Release all Tamiflu data as promised, argue researchers

Company plans to set up review board, but researchers want it to keep its promise

2012-11-26

(Press-News.org) The latest correspondence is posted online today as part of the BMJ's open data campaign, aimed at persuading Roche to honour the promise it made almost three years ago to make key Tamiflu trial data available for independent scrutiny.

Last week, Donald MacLean, Life Cycle Leader for Tamiflu, wrote to Professor Chris Del Mar in his capacity as coordinating editor of the Cochrane Acute Respiratory Infections Group, concerning "our debate on Tamiflu data."

The Cochrane researchers say they object to Roche's suggestion that there is a debate on Tamiflu data. "There is no debate nor can there be any debate about the data whilst you do not honour your promise," they say. "The only reason we keep asking Roche to keep its promise, rather than simply getting the data from the European Medicines Agency directly, is because Roche has not supplied all of the data to the European regulator."

Roche's letter also mentions "disagreements" over the type of analyses the Cochrane team wish to do, but the researchers point out that their methods and analyses have been public for nearly two years and "follow Cochrane procedure" and state that they are not aware of any specific concerns from Roche.

Roche's letter goes on to say that, in order to reach "an amicable resolution" Roche plans to set up "a multi-party advisory board to review the totality of Tamiflu data" …. which they believe is "a sensible, fair and transparent way of addressing this public debate."

But the Cochrane team argue that Roche's offer is merely a belated attempt at turning the clock back, and call on the company to expand its data sharing pledges "to become compatible with current regulatory norms."

They say: "The European Medicines Agency and the EU Ombudsman have made abundantly clear that there is no reason for anonymised clinical data to be withheld from public scrutiny once a marketing authorisation has been obtained for a pharmaceutical. Why should Roche not - at the minimum - meet this standard?"

In summary, they say, "we ask to you to honour your promise of three years ago and make public full clinical study reports in your possession."

### END

ELSE PRESS RELEASES FROM THIS DATE:

How does a volcanic crater grow? Grab some TNT and find out

2012-11-26

BUFFALO, N.Y. -- A new University at Buffalo study in the journal Geophysical Research Letters examines maar craters, which resemble the bowl-like cavities formed by meteorites but are in some ways more mysterious. Scientists often can discern pertinent details about meteorites -- when they struck, how large they were, the angle they approached Earth and other information -- by measuring the diameter and volume of the impact crater. Maar craters, which form when fissures of magma beneath Earth's surface meet groundwater, causing volcanic explosions, are not as telling, ...

BioMAP screening procedure could streamline search for new antibiotics

2012-11-26

Researchers at the University of California, Santa Cruz, have developed a new strategy for finding novel antibiotic compounds, using a diagnostic panel of bacterial strains for screening chemical extracts from natural sources. Public health officials warn of a looming antibiotic crisis due to the steady increase in antibiotic resistance and a dramatic decline in the development of new antibiotics. Most currently available antibiotics are derived from natural compounds produced by microorganisms such as bacteria and fungi. New antibiotics developed by drug companies are ...

New device hides, on cue, from infrared cameras

2012-11-26

Cambridge, Mass. - November 26, 2012 - Now you see it, now you don't. A new device invented at the Harvard School of Engineering and Applied Sciences (SEAS) can absorb 99.75% of infrared light that shines on it. When activated, it appears black to infrared cameras. Composed of just a 180-nanometer-thick layer of vanadium dioxide (VO2) on top of a sheet of sapphire, the device reacts to temperature changes by reflecting dramatically more or less infrared light. Announced today in the journal Applied Physics Letters, and featured on its cover, this perfect absorber ...

Seizures linked to surgery drugs can be prevented by anesthetics, U of T team finds

2012-11-26

Two drugs commonly given during cardiac surgery can lead to convulsive seizures, but anesthetics can help cut the risk, according to new research from the Faculty of Medicine at the University of Toronto. Patients undergoing complex heart operations or trauma surgery are often given tranexamic acid (TXA) and aminocaproic acid (EACA) to reduce blood loss. But Faculty of Medicine researchers found these drugs are associated with a four-to-six-fold increase in post-operative seizures. The risk is highest for cardiac surgery patients – between three and seven and a half per ...

Researchers test novel power system for space travel

2012-11-26

LOS ALAMOS, N.M., Nov. 26, 2012 — A team of researchers, including engineers from Los Alamos National Laboratory, has demonstrated a new concept for a reliable nuclear reactor that could be used on space flights. The research team recently demonstrated the first use of a heat pipe to cool a small nuclear reactor and power a Stirling engine at the Nevada National Security Site's Device Assembly Facility near Las Vegas. The Demonstration Using Flattop Fissions (DUFF) experiment produced 24 watts of electricity. A team of engineers from Los Alamos, the NASA Glenn Research ...

Cyber Monday at CocktailNerd Brings the Biggest E-Cig Savings of 2012

2012-11-26

Cyber Monday is here and it brings one last chance for electronic cigarette fans to save big on all of their favorite e-cig starter kits and accessories. CocktailNerd.com is offering readers big savings on Cyber Monday with exclusive deals that will expire at midnight. This is the year's biggest sale on all of the best electronic cigarettes brands and with exclusive coupon codes from Cocktail Nerd, e-cig shoppers can save up to 65% on all of their favorite products. Cocktail Nerd is the Internet's most cutting edge website for e-cig news, reviews, and savings. The site ...

Alzheimer's disease in mice alleviated promising therapeutic approach for humans

2012-11-26

Alzheimer's disease is one of the most common causes of dementia. In Germany and Switzerland alone, around 1.5 million people are affected, and forecasts predict a doubling of the number of patients worldwide within the next 20 years. The accumulation of particular abnormal proteins, including amyloid-ß (Aβ) among others, in patients' brains plays a central role in this disease. Prof. Frank Heppner from the Department of Neuropathology at Charité and his colleague Prof. Burkhard Becher from the Institute for Experimental Immunology at the University of Zurich were ...

Patient's own immune cells may blunt viral therapy for brain cancer

2012-11-26

COLUMBUS, Ohio – Doctors now use cancer-killing viruses to treat some patients with lethal, fast-growing brain tumors. Clinical trials show that these therapeutic viruses are safe but less effective than expected. A new study led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) shows that the reason for this is in part due to the patient's own immune system, which quickly works to eliminate the anticancer virus. The findings, published in the journal Nature ...

Temple-Penn researchers identify calcium 'accelerator' to keep cell power supply going

2012-11-26

(Philadelphia, PA) – A team of scientists from Temple University School of Medicine and the University of Pennsylvania has moved another step closer to solving a decades-long mystery of how the all-important flow of calcium into the cell's power source, the mitochondria, is controlled. By painstakingly shutting down the activity of 50 genes, one at a time, they have identified a protein, MCUR1, which hugs the inside of the mitochondrial membrane and is part of an elaborate mitochondrial channel pore system. MCUR1 acts as an accelerator to help regulate calcium coming ...

Exercise rate related to improvements in Parkinson’s disease

2012-11-26

CHICAGO – People with Parkinson's disease benefit from exercise programs on stationary bicycles, with the greatest effect for those who pedal faster, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA). Functional connectivity magnetic resonance imaging (fcMRI) data showed that faster pedaling led to greater connectivity in brain areas associated with motor ability. Parkinson's disease is a chronic, progressive disorder of the central nervous system. Early-stage symptoms like shaking and difficulty with walking ...

Release all Tamiflu data as promised, argue researchers

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: